Oligonucleotide Synthesis Market by Product (Probe, Linkers, Adaptor, Drugs, Reagent, Equipment), Type (Custom, Pre design), Application (PCR, DNA, RNAi, Research, Therapeutic), End User (Hospital, Pharmaceutical, Biotechnology) - Global Forecast to 2024

オリゴヌクレオチド合成の世界市場予測(~2024年)

◆タイトル:Oligonucleotide Synthesis Market by Product (Probe, Linkers, Adaptor, Drugs, Reagent, Equipment), Type (Custom, Pre design), Application (PCR, DNA, RNAi, Research, Therapeutic), End User (Hospital, Pharmaceutical, Biotechnology) - Global Forecast to 2024
◆商品コード:BT-2680
◆調査・発行会社:MarketsandMarkets
◆発行日:2019年4月29日
◆ページ数:157
◆レポート形式:PDF / 英語
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル
◆産業分野:バイオテクノロジー
◆販売価格オプション(消費税別)
Single User(1名様閲覧)USD5,650 ⇒換算¥621,500見積依頼/購入/質問フォーム
Multi User (Five User)USD6,650 ⇒換算¥731,500見積依頼/購入/質問フォーム
Corporate License (全社内共有可)USD8,150 ⇒換算¥896,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※商品の納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※ご購入後、レポートに記載の英語表現や単語の意味に関しましては無料でお答えいたします。(但し、対応範囲は弊社で判断)
※弊社H&Iグローバルリサーチ株式会社はMarketsandMarketsの日本における正規販売代理店です。

【レポートの概要】

当調査レポートでは、オリゴヌクレオチド合成の世界市場について調査・分析し、エグゼクティブサマリー、市場インサイト、市場概観/市場動向、製品別(プローブ、リンカー、アダプター、医薬品、試薬、装置)分析、種類別(カスタム、 プレデザイン)分析、用途別(PCR、DNA、RNAi、リサーチ、治療)分析、エンドユーザー別(病院、医薬品、バイオテクノロジー)分析、オリゴヌクレオチド合成の世界市場規模及び予測、市場動向、競争状況、関連企業分析などの情報をお届けいたします。

“Increasing R&D expenditure by pharmaceutical and biotechnology companies and the rising demand for synthesized oligos in molecular diagnostics & therapeutics are expected to drive the overall growth of the oligonucleotide synthesis market”The global oligonucleotide synthesis market is projected to reach USD 8.2 billion by 2024 from USD 4.3 billion in 2019, at a CAGR of 13.7% during the forecast period. This market is experiencing significant growth due to the increasing research activities in the pharma and biotech sectors and the rising demand for innovative diagnostic and therapeutic techniques. The increasing applications of oligos in nucleic acid array-based technologies, library preparation, NGS, genomics, nucleic acid-based detection, cell cultures, diagnostics, therapeutics, human identity testing, cloning, genetic engineering, and synthetic biology are also driving the growth of this market.

“Hospitals accounted for the largest share of the oligonucleotide synthesis market, by end user, in 2018”
Based on end user, the oligonucleotide synthesis market is segmented into academic research institutes, pharmaceutical and biotechnology companies, diagnostic laboratories, and hospitals. Hospitals held the largest share of the market in 2018 due to the significant number of inpatient and outpatient visits in hospitals and the requirement of oligonucleotide drugs to cater to the demand of the patient pool suffering from diseases such as Duchenne muscular dystrophy, spinal muscular atrophy, and hepatic veno-occlusive disease.
“Synthesized oligos dominated the oligonucleotide synthesis market, by product, in 2018
Based on product, the market is segmented into synthesized oligos, reagents, and equipment. The synthesized oligos segment held the largest share of the market in 2018 and is estimated to grow at the highest CAGR during the forecast period. Growth in this segment is attributed to the increasing applications of synthesized oligos in therapeutics, research, and diagnostics.

“North America to dominate the market during the forecast period”
Geographically, the oligonucleotide synthesis market is segmented into North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa. In 2018, North America was the largest regional market for oligonucleotide synthesis. The North American market is also estimated to grow at the highest CAGR during the forecast period owing to the growing availability of synthesized oligos, along with an increase in R&D funding and activities in the North American region.

The primary interviews conducted for this report can be categorized as follows:
• By Company Type – Tier 1: 35%, Tier 2: 45%, and Tier 3: 20%
• By Designation – C-level: 45%, D-level: 35%, and Others: 20%
• By Region – North America: 45%, Europe: 25%, Asia Pacific: 18%, Latin America: 7%, and Middle East and Africa: 3%

List of Companies Profiled in the Report
• include Agilent Technologies, Inc. (US)
• ATDBio Ltd. (UK)
• Bio-Synthesis, Inc. (US)
• BioAutomation Corporation (US)
• LGC Biosearch Technologies (US)
• Eurofins Genomics (Germany)
• Eurogentec (Belgium)
• GeneDesign, Inc. (Japan)
• GE Healthcare (US)
• GenScript, Inc. (US)
• Integrated DNA Technologies (IDT, US)
• Nitto Denko Avecia, Inc. (US)
• Sarepta Therapeutics (US)
• Thermo Fisher Scientific, Inc. (US)
• TriLink BioTechnologies (US)
• Sigma-Aldrich Corporation (US) (a part of Merck KGAA)

Research Coverage:
This report provides a detailed picture of the global oligonucleotide synthesis market. It aims at estimating the size and future growth potential of the market across different segments, such as product & type, application, end user, and region. The report also includes an in-depth competitive analysis of the key market players, along with their company profiles, recent developments, and key market strategies.

Key Benefits of Buying the Report:
The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall oligonucleotide synthesis market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the pulse of the market and provide them with information on the key market drivers, restraints, challenges, and opportunities.

【レポートの目次】

TABLE OF CONTENTS

1 INTRODUCTION 21
1.1 OBJECTIVES OF THE STUDY 21
1.2 DEFINITION 21
1.3 MARKET SCOPE 22
1.3.1 MARKETS COVERED 22
1.3.2 YEARS CONSIDERED FOR THE STUDY 22
1.4 CURRENCY 23
1.5 LIMITATIONS 23
1.6 STAKEHOLDERS 23
2 RESEARCH METHODOLOGY 24
2.1 RESEARCH DATA 24
2.2 SECONDARY DATA 25
2.2.1 SECONDARY SOURCES 25
2.3 PRIMARY DATA 26
2.3.1 KEY DATA FROM PRIMARY SOURCES 26
2.4 MARKET SIZE ESTIMATION 27
2.4.1 MARKET SIZE ESTIMATION: BOTTOM-UP APPROACH 27
2.4.2 MARKET SIZE ESTIMATION: TOP-DOWN APPROACH 28
2.5 MARKET BREAKDOWN AND DATA TRIANGULATION 29
2.6 ASSUMPTIONS FOR THE STUDY 30
3 EXECUTIVE SUMMARY 31
4 PREMIUM INSIGHTS 36
4.1 ATTRACTIVE OPPORTUNITIES IN THE OLIGONUCLEOTIDE SYNTHESIS MARKET 36
4.2 SYNTHESIZED OLIGOS MARKET, BY PRODUCT 37
4.3 SYNTHESIZED OLIGOS MARKET, BY TYPE 37
4.4 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY RESEARCH APPLICATION AND COUNTRY (2019) 38
4.5 OLIGONUCLEOTIDE SYNTHESIS MARKET, BY THERAPEUTIC APPLICATION 39
4.6 OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER 39
4.7 GEOGRAPHIC SNAPSHOT: OLIGONUCLEOTIDE SYNTHESIS MARKET 40

5 MARKET OVERVIEW 41
5.1 INTRODUCTION 41
5.2 MARKET DYNAMICS 41
5.2.1 MARKET DRIVERS 42
5.2.1.1 Increasing use of synthesized oligos in molecular diagnostics and clinical applications 42
5.2.1.2 Increasing government investments and R&D expenditure in pharmaceutical and biotechnology companies 43
5.2.1.3 Rise in venture capital investments 44
5.2.2 MARKET RESTRAINTS 45
5.2.2.1 Price erosion of synthesized oligos 45
5.2.2.2 Lack of a unified set of regulations for therapeutic oligos 45
5.2.3 MARKET OPPORTUNITIES 46
5.2.3.1 Emerging Asian markets 46
5.2.4 MARKET CHALLENGES 47
5.2.4.1 Large-scale synthesis of oligos 47
5.2.4.2 Delivery of oligonucleotide drugs to specific targets 47
6 OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT 48
6.1 INTRODUCTION 49
6.2 SYNTHESIZED OLIGOS 50
6.2.1 SYNTHESIZED OLIGOS MARKET, BY PRODUCT 51
6.2.1.1 Oligonucleotide-based drugs 52
6.2.1.1.1 Oligonucleotide-based drugs dominate the synthesized oligos market, by product 52
6.2.1.2 Primers 53
6.2.1.2.1 Growing research activity drives the market for primers 53
6.2.1.3 Probes 54
6.2.1.3.1 Probes are designed to detect various infectious agents 54
6.2.1.4 Intermediate-scale synthesized oligos 55
6.2.1.4.1 The increasing demand for synthesized oligos and innovations in manufacturing techniques drives the market. 55
6.2.1.5 Large-scale synthesized oligos 56
6.2.1.5.1 Increasing demand for large quantities of modified and unmodified oligos to drive the market 56
6.2.1.6 Linkers & Adaptors 57
6.2.1.6.1 Linkers are used to add restriction sites in DNA 57
6.2.2 SYNTHESIZED OLIGOS MARKET, BY TYPE 58
6.2.2.1 Predesigned oligos 58
6.2.2.1.1 Predesigned oligos dominate the oligonucleotide synthesis market, by type 58
6.2.2.2 Custom oligos 59
6.2.2.2.1 Increasing number of clinical and pre-clinical research to drive the market for custom oligos 59
6.3 REAGENTS 60
6.4 EQUIPMENT 61
7 OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION 63
7.1 INTRODUCTION 64
7.2 THERAPEUTIC APPLICATIONS 65
7.2.1 DNA & ANTISENSE OLIGONUCLEOTIDE-BASED THERAPIES 67
7.2.1.1 DNA & antisense oligos form the largest segment in the therapeutic applications market 67
7.2.2 RNAI OLIGONUCLEOTIDE-BASED THERAPIES 68
7.2.2.1 Significant initiatives by pharmaceutical and biotechnology companies to drive the market for RNAi oligonucleotide-based therapies 68
7.2.3 CPG OLIGONUCLEOTIDE-BASED THERAPIES 69
7.2.3.1 This market segment is in the initial stage, and significant growth might be observed during the forecast period 69
7.3 DIAGNOSTIC APPLICATIONS 70
7.4 RESEARCH APPLICATIONS 71
7.4.1 PCR 73
7.4.1.1 Increasing use of PCR in research to drive market growth 73
7.4.2 QPCR 74
7.4.2.1 Its cost-effectiveness, concurrent monitoring of expression levels of multiple genetic messages in real time, and high sensitivity make QPCR a vital tool for quantification of nucleic acids 74
7.4.3 SEQUENCING 75
7.4.3.1 Advancements in sequencing technologies and low cost to drive the market for sequencing applications 75
7.4.4 GENE SYNTHESIS 76
7.4.4.1 Increasing applications of gene synthesis and low cost to drive the market for this application segment 76
7.4.5 OTHER RESEARCH APPLICATIONS 77
8 OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER 78
8.1 INTRODUCTION 79
8.2 HOSPITALS 80
8.2.1 HOSPITALS ARE THE LARGEST END USERS OF OLIGOS DUE TO THE SIGNIFICANT NUMBER OF INPATIENT AND OUTPATIENT VISITS 80
8.3 ACADEMIC RESEARCH INSTITUTES 81
8.3.1 ACADEMIC RESEARCHERS PRIMARILY USE OLIGOS FOR GENETIC ENGINEERING, PCR ACTIVITIES, AND HIGH-THROUGHPUT SEQUENCING—A MAJOR FACTOR DRIVING MARKET GROWTH 81
8.4 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 82
8.4.1 GROWING APPLICATIONS OF OLIGOS IN DRUG DISCOVERY & THERAPEUTICS TO DRIVE THE DEMAND FOR OLIGONUCLEOTIDE SYNTHESIS AMONG THESE END USERS 82

8.5 DIAGNOSTIC LABORATORIES 84
8.5.1 DIAGNOSTIC LABORATORIES REGISTER HIGH GROWTH IN
THE OLIGONUCLEOTIDE SYNTHESIS MARKET DUE TO THE INCREASING SIGNIFICANCE OF OLIGOS IN MOLECULAR DIAGNOSTICS 84
9 OLIGONUCLEOTIDE SYNTHESIS MARKET, BY REGION 85
9.1 INTRODUCTION 86
9.2 NORTH AMERICA 87
9.2.1 US 92
9.2.1.1 Government initiatives and strategic developments by market players to drive market growth in the country 92
9.2.2 CANADA 95
9.2.2.1 Growing initiatives and funding in synthetic biology and genomics to drive the market in the country 95
9.3 EUROPE 99
9.3.1 GERMANY 104
9.3.1.1 Presence of a large number of academic research institutes to support market growth 104
9.3.2 FRANCE 107
9.3.2.1 Government initiatives to boost R&D activities in the country 107
9.3.3 UK 111
9.3.3.1 Growth in the life science industry to drive the market for oligonucleotides synthesis in the UK 111
9.3.4 ITALY 114
9.3.4.1 Increasing research activities to drive the market for oligonucleotides synthesis in Italy 114
9.3.5 SPAIN 117
9.3.5.1 Government initiatives to drive the market for
oligonucleotide synthesis 117
9.3.6 ROE 121
9.4 ASIA PACIFIC 125
9.4.1 CHINA 131
9.4.1.1 Government initiatives to strengthen the biotechnology industry
in China 131
9.4.2 JAPAN 135
9.4.2.1 Increasing awareness through conferences and workshops to drive the market in the country 135
9.4.3 INDIA 138
9.4.3.1 Government initiatives to promote synthetic biology to drive
the market in the country 138
9.4.4 ROAPAC 142
9.5 LATIN AMERICA 146
9.5.1 BRAZIL 151
9.5.1.1 Development in genomics to aid market growth in Brazil 151

9.5.2 MEXICO 152
9.5.2.1 Increasing awareness about advancements in oligonucleotides to drive the market 152
9.5.3 ROLATAM 154
9.6 MIDDLE EAST & AFRICA 156
10 COMPETITIVE LANDSCAPE 162
10.1 OVERVIEW 162
10.2 MARKET SHARE ANALYSIS 163
10.3 COMPETITIVE SCENARIO 166
10.3.1 PARTNERSHIPS, AGREEMENTS, CONTRACTS, AND COLLABORATIONS 166
10.3.2 PRODUCT LAUNCHES, UPGRADES, AND APPROVALS 167
10.3.3 EXPANSIONS 167
10.3.4 ACQUISITIONS 168
10.4 COMPETITIVE LEADERSHIP MAPPING (2017) 169
10.4.1 VANGUARDS 169
10.4.2 INNOVATORS 169
10.4.3 DYNAMIC PLAYERS 169
10.4.4 EMERGING PLAYERS 169
10.5 COMPETITIVE LEADERSHIP MAPPING FOR START-UPS (2018) 171
10.5.1 PROGRESSIVE COMPANIES 171
10.5.2 STARTING BLOCKS 171
10.5.3 RESPONSIVE COMPANIES 171
10.5.4 DYNAMIC COMPANIES 171
10.6 MNM DIVE-VENDOR COMPARISON MATRIX FOR START-UPS:
OLIGONUCLEOTIDE SYNTHESIS MARKET 172
11 COMPANY PROFILES 173
(Business Overview, Products/Services Offered, Recent Developments, and MnM View)*
11.1 AGILENT TECHNOLOGIES 173
11.2 ADTBIO 177
11.3 BIOAUTOMATION (ACQUIRED BY LGC) 178
11.4 BIO-SYNTHESIS INC. 181
11.5 EUROFINS GENOMICS 183
11.6 EUROGENTEC 186
11.7 GE HEALTHCARE 190
11.8 GENSCRIPT 193
11.9 GENEDESIGN (PART OF AJINOMOTO) 196
11.10 INTEGRATED DNA TECHNOLOGIES (ACQUIRED BY DANAHER CORPORATION) 198
11.11 LGC BIOSEARCH TECHNOLOGIES 203
11.12 MERCK KGAA 204
11.13 NITTO DENKO AVECIA 208
11.14 THERMO FISHER SCIENTIFIC 211
11.15 TRILINK BIOTECHNOLOGIES (PART OF MARAVAI LIFESCIENCES) 216
* Business Overview, Products/Services Offered, Recent Developments, and MnM View might not be captured in case of unlisted companies.
12 APPENDIX 218
12.1 INSIGHTS FROM INDUSTRY EXPERTS 218
12.2 DISCUSSION GUIDE 219
12.3 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 222
12.4 AVAILABLE CUSTOMIZATIONS 224
12.5 RELATED REPORTS 224
12.6 AUTHOR DETAILS 225

LIST OF TABLES

TABLE 1 FDA-APPROVED OLIGONUCLEOTIDE-BASED THERAPIES 42
TABLE 2 OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT,
2017–2024 (USD MILLION) 49
TABLE 3 SYNTHESIZED OLIGOS MARKET, BY REGION, 2017–2024 (USD MILLION) 50
TABLE 4 SYNTHESIZED OLIGOS MARKET, BY PRODUCT, 2017–2024 (USD MILLION) 51
TABLE 5 LATE-STAGE OLIGONUCLEOTIDE-BASED THERAPIES 52
TABLE 6 OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY REGION,
2017–2024 (USD MILLION) 52
TABLE 7 PRIMERS MARKET, BY REGION, 2017–2024 (USD MILLION) 53
TABLE 8 PROBES MARKET, BY REGION, 2017–2024 (USD MILLION) 54
TABLE 9 OLIGONUCLEOTIDE SYNTHESIS MARKET FOR INTERMEDIATE-SCALE
SYNTHESIZED OLIGOS, BY REGION, 2017–2024 (USD MILLION) 55
TABLE 10 LARGE-SCALE SYNTHESIZED OLIGOS MARKET, BY REGION,
2017–2024 (USD MILLION) 56
TABLE 11 LINKERS & ADAPTORS MARKET, BY REGION, 2017–2024 (USD MILLION) 57
TABLE 12 SYNTHESIZED OLIGOS MARKET, BY TYPE, 2017–2024 (USD MILLION) 58
TABLE 13 PREDESIGNED OLIGOS MARKET, BY REGION, 2017–2024 (USD MILLION) 59
TABLE 14 CUSTOM OLIGOS MARKET, BY REGION, 2017–2024 (USD MILLION) 60
TABLE 15 OLIGONUCLEOTIDE SYNTHESIS REAGENTS MARKET, BY REGION,
2017–2024 (USD MILLION) 61
TABLE 16 OLIGONUCLEOTIDE SYNTHESIS EQUIPMENT MARKET, BY REGION,
2017–2024 (USD MILLION) 62
TABLE 17 OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION,
2017–2024 (USD MILLION) 64
TABLE 18 OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS,
BY TYPE, 2017–2024 (USD MILLION) 66
TABLE 19 OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS,
BY REGION, 2017–2024 (USD MILLION) 66
TABLE 20 ANTISENSE OLIGONUCLEOTIDES IN CLINICAL TRIALS 67
TABLE 21 OLIGONUCLEOTIDE SYNTHESIS MARKET FOR DNA & ANTISENSE OLIGONUCLEOTIDE-BASED THERAPIES, BY REGION, 2017–2024 (USD MILLION) 67
TABLE 22 OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RNAI OLIGONUCLEOTIDE-BASED THERAPIES, BY REGION, 2017–2024 (USD MILLION) 69
TABLE 23 OLIGONUCLEOTIDE SYNTHESIS MARKET FOR CPG OLIGONUCLEOTIDE-BASED THERAPIES, BY REGION, 2017–2024 (USD MILLION) 70
TABLE 24 OLIGONUCLEOTIDE SYNTHESIS MARKET FOR DIAGNOSTIC APPLICATIONS,
BY REGION, 2017–2024 (USD MILLION) 71
TABLE 25 OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS,
BY REGION, 2017–2024 (USD MILLION) 72
TABLE 26 OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2017–2024 (USD MILLION) 72
TABLE 27 OLIGONUCLEOTIDE SYNTHESIS MARKET FOR PCR APPLICATIONS, BY REGION, 2017–2024 (USD MILLION) 73
TABLE 28 OLIGONUCLEOTIDE SYNTHESIS MARKET FOR QPCR APPLICATIONS, BY REGION, 2017–2024 (USD MILLION) 74
TABLE 29 OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SEQUENCING APPLICATIONS,
BY REGION, 2017–2024 (USD MILLION) 75
TABLE 30 OLIGONUCLEOTIDE SYNTHESIS MARKET FOR GENE SYNTHESIS APPLICATIONS,
BY REGION, 2017–2024 (USD MILLION) 76
TABLE 31 OLIGONUCLEOTIDE SYNTHESIS MARKET FOR OTHER RESEARCH APPLICATIONS,
BY REGION, 2017–2024 (USD MILLION) 77
TABLE 32 OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER,
2017–2024 (USD MILLION) 79
TABLE 33 OLIGONUCLEOTIDE SYNTHESIS MARKET FOR HOSPITALS, BY REGION,
2017–2024 (USD MILLION) 80
TABLE 34 OLIGONUCLEOTIDE SYNTHESIS MARKET FOR ACADEMIC RESEARCH INSTITUTES, BY REGION, 2017–2024 (USD MILLION) 82
TABLE 35 OLIGONUCLEOTIDE SYNTHESIS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2017–2024 (USD MILLION) 83
TABLE 36 OLIGONUCLEOTIDE SYNTHESIS MARKET FOR DIAGNOSTIC LABORATORIES,
BY REGION, 2017–2024 (USD MILLION) 84
TABLE 37 OLIGONUCLEOTIDE SYNTHESIS MARKET, BY REGION, 2017–2024 (USD MILLION) 86
TABLE 38 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY COUNTRY,
2017–2024 (USD MILLION) 88
TABLE 39 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT,
2017–2024 (USD MILLION) 88
TABLE 40 NORTH AMERICA: SYNTHESIZED OLIGOS MARKET, BY PRODUCT,
2017–2024 (USD MILLION) 89
TABLE 41 NORTH AMERICA: SYNTHESIZED OLIGOS MARKET, BY TYPE,
2017–2024 (USD MILLION) 89
TABLE 42 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2017–2024 (USD MILLION) 90
TABLE 43 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2017–2024 (USD MILLION) 90
TABLE 44 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2017–2024 (USD MILLION) 91
TABLE 45 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER,
2017–2024 (USD MILLION) 91
TABLE 46 US: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT,
2017–2024 (USD MILLION) 92
TABLE 47 US: SYNTHESIZED OLIGOS MARKET, BY PRODUCT, 2017–2024 (USD MILLION) 93
TABLE 48 US: SYNTHESIZED OLIGOS MARKET, BY TYPE, 2017–2024 (USD MILLION) 93
TABLE 49 US: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION,
2017–2024 (USD MILLION) 94
TABLE 50 US: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS,
BY TYPE, 2017–2024 (USD MILLION) 94
TABLE 51 US: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER,
2017–2024 (USD MILLION) 95
TABLE 52 CANADA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT,
2017–2024 (USD MILLION) 96
TABLE 53 CANADA: SYNTHESIZED OLIGOS MARKET, BY PRODUCT,
2017–2024 (USD MILLION) 96
TABLE 54 CANADA: SYNTHESIZED OLIGOS MARKET, BY TYPE, 2017–2024 (USD MILLION) 97
TABLE 55 CANADA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION,
2017–2024 (USD MILLION) 97
TABLE 56 CANADA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2017–2024 (USD MILLION) 98
TABLE 57 CANADA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER,
2017–2024 (USD MILLION) 98
TABLE 58 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY COUNTRY,
2017–2024 (USD MILLION) 100
TABLE 59 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT,
2017–2024 (USD MILLION) 100
TABLE 60 EUROPE: SYNTHESIZED OLIGOS MARKET, BY PRODUCT,
2017–2024 (USD MILLION) 101
TABLE 61 EUROPE: SYNTHESIZED OLIGOS MARKET, BY TYPE, 2017–2024 (USD MILLION) 101
TABLE 62 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION,
2017–2024 (USD MILLION) 102
TABLE 63 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2017–2024 (USD MILLION) 102
TABLE 64 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2017–2024 (USD MILLION) 103
TABLE 65 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER,
2017–2024 (USD MILLION) 103
TABLE 66 GERMANY: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT,
2017–2024 (USD MILLION) 104
TABLE 67 GERMANY: SYNTHESIZED OLIGOS MARKET, BY PRODUCT,
2017–2024 (USD MILLION) 105
TABLE 68 GERMANY: SYNTHESIZED OLIGOS MARKET, BY TYPE, 2017–2024 (USD MILLION) 105
TABLE 69 GERMANY: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION,
2017–2024 (USD MILLION) 106
TABLE 70 GERMANY: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2017–2024 (USD MILLION) 106
TABLE 71 GERMANY: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER,
2017–2024 (USD MILLION) 107
TABLE 72 FRANCE: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT,
2017–2024 (USD MILLION) 108
TABLE 73 FRANCE: SYNTHESIZED OLIGOS MARKET, BY PRODUCT,
2017–2024 (USD MILLION) 108
TABLE 74 FRANCE: SYNTHESIZED OLIGOS MARKET, BY TYPE, 2017–2024 (USD MILLION) 109
TABLE 75 FRANCE: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION,
2017–2024 (USD MILLION) 109
TABLE 76 FRANCE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2017–2024 (USD MILLION) 110
TABLE 77 FRANCE: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER,
2017–2024 (USD MILLION) 110
TABLE 78 UK: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT,
2017–2024 (USD MILLION) 111
TABLE 79 UK: SYNTHESIZED OLIGOS MARKET, BY PRODUCT, 2017–2024 (USD MILLION) 112
TABLE 80 UK: SYNTHESIZED OLIGOS MARKET, BY TYPE, 2017–2024 (USD MILLION) 112
TABLE 81 UK: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION,
2017–2024 (USD MILLION) 113
TABLE 82 UK: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS,
BY TYPE, 2017–2024 (USD MILLION) 113
TABLE 83 UK: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER,
2017–2024 (USD MILLION) 114
TABLE 84 ITALY: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT,
2017–2024 (USD MILLION) 114
TABLE 85 ITALY: SYNTHESIZED OLIGOS MARKET, BY PRODUCT, 2017–2024 (USD MILLION) 115
TABLE 86 ITALY: SYNTHESIZED OLIGOS MARKET, BY TYPE, 2017–2024 (USD MILLION) 115
TABLE 87 ITALY: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION,
2017–2024 (USD MILLION) 116
TABLE 88 ITALY: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS,
BY TYPE, 2017–2024 (USD MILLION) 116
TABLE 89 ITALY: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER,
2017–2024 (USD MILLION) 117
TABLE 90 SPAIN: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT,
2017–2024 (USD MILLION) 118
TABLE 91 SPAIN: SYNTHESIZED OLIGOS MARKET, BY PRODUCT, 2017–2024 (USD MILLION) 118
TABLE 92 SPAIN: SYNTHESIZED OLIGOS MARKET, BY TYPE, 2017–2024 (USD MILLION) 119
TABLE 93 SPAIN: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION,
2017–2024 (USD MILLION) 119
TABLE 94 SPAIN: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS,
BY TYPE, 2017–2024 (USD MILLION) 120
TABLE 95 SPAIN: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER,
2017–2024 (USD MILLION) 120
TABLE 96 ROE: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT,
2017–2024 (USD MILLION) 121
TABLE 97 ROE: SYNTHESIZED OLIGOS MARKET, BY PRODUCT, 2017–2024 (USD MILLION) 122
TABLE 98 ROE: SYNTHESIZED OLIGOS MARKET, BY TYPE, 2017–2024 (USD MILLION) 122
TABLE 99 ROE: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION,
2017–2024 (USD MILLION) 123
TABLE 100 ROE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS,
BY TYPE, 2017–2024 (USD MILLION) 123
TABLE 101 ROE: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER,
2017–2024 (USD MILLION) 124
TABLE 102 APAC: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY COUNTRY,
2017–2024 (USD MILLION) 127
TABLE 103 APAC: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT,
2017–2024 (USD MILLION) 127
TABLE 104 APAC: SYNTHESIZED OLIGOS MARKET, BY PRODUCT, 2017–2024 (USD MILLION) 128
TABLE 105 APAC: SYNTHESIZED OLIGOS MARKET, BY TYPE, 2017–2024 (USD MILLION) 128
TABLE 106 APAC: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION,
2017–2024 (USD MILLION) 129
TABLE 107 APAC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS,
BY TYPE, 2017–2024 (USD MILLION) 129
TABLE 108 APAC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2017–2024 (USD MILLION) 130
TABLE 109 APAC: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER,
2017–2024 (USD MILLION) 130
TABLE 110 CHINA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT,
2017–2024 (USD MILLION) 132
TABLE 111 CHINA: SYNTHESIZED OLIGOS MARKET, BY PRODUCT, 2017–2024 (USD MILLION) 132
TABLE 112 CHINA: SYNTHESIZED OLIGOS MARKET, BY TYPE, 2017–2024 (USD MILLION) 133
TABLE 113 CHINA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION,
2017–2024 (USD MILLION) 133
TABLE 114 CHINA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS,
BY TYPE, 2017–2024 (USD MILLION) 134
TABLE 115 CHINA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER,
2017–2024 (USD MILLION) 134
TABLE 116 JAPAN: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT,
2017–2024 (USD MILLION) 135
TABLE 117 JAPAN: SYNTHESIZED OLIGOS MARKET, BY PRODUCT, 2017–2024 (USD MILLION) 136
TABLE 118 JAPAN: SYNTHESIZED OLIGOS MARKET, BY TYPE, 2017–2024 (USD MILLION) 136
TABLE 119 JAPAN: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION,
2017–2024 (USD MILLION) 137
TABLE 120 JAPAN: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS,
BY TYPE, 2017–2024 (USD MILLION) 137
TABLE 121 JAPAN: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER,
2017–2024 (USD MILLION) 138
TABLE 122 INDIA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT,
2017–2024 (USD MILLION) 139
TABLE 123 INDIA: SYNTHESIZED OLIGOS MARKET, BY PRODUCT, 2017–2024 (USD MILLION) 139
TABLE 124 INDIA: SYNTHESIZED OLIGOS MARKET, BY TYPE, 2017–2024 (USD MILLION) 140
TABLE 125 INDIA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION,
2017–2024 (USD MILLION) 140
TABLE 126 INDIA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS,
BY TYPE, 2017–2024 (USD MILLION) 141
TABLE 127 INDIA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER,
2017–2024 (USD MILLION) 141
TABLE 128 ROAPAC: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT,
2017–2024 (USD MILLION) 142
TABLE 129 ROAPAC: SYNTHESIZED OLIGOS MARKET, BY PRODUCT,
2017–2024 (USD MILLION) 143
TABLE 130 ROAPAC: SYNTHESIZED OLIGOS MARKET, BY TYPE, 2017–2024 (USD MILLION) 143
TABLE 131 ROAPAC: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION,
2017–2024 (USD MILLION) 144
TABLE 132 ROAPAC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2017–2024 (USD MILLION) 144
TABLE 133 ROAPAC: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER,
2017–2024 (USD MILLION) 145
TABLE 134 LATAM: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY COUNTRY,
2017–2024 (USD MILLION) 147
TABLE 135 LATAM: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT,
2017–2024 (USD MILLION) 147
TABLE 136 LATAM: SYNTHESIZED OLIGOS MARKET, BY PRODUCT, 2017–2024 (USD MILLION) 148
TABLE 137 LATAM: SYNTHESIZED OLIGOS MARKET, BY TYPE, 2017–2024 (USD MILLION) 148
TABLE 138 LATAM: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION,
2017–2024 (USD MILLION) 149
TABLE 139 LATAM: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2017–2024 (USD MILLION) 149
TABLE 140 LATAM: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2017–2024 (USD MILLION) 150
TABLE 141 LATAM: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER,
2017–2024 (USD MILLION) 150
TABLE 142 BRAZIL: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT,
2017–2024 (USD MILLION) 151
TABLE 143 BRAZIL: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION,
2017–2024 (USD MILLION) 151
TABLE 144 BRAZIL: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER,
2017–2024 (USD MILLION) 152
TABLE 145 MEXICO: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT,
2017–2024 (USD MILLION) 153
TABLE 146 MEXICO: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION,
2017–2024 (USD MILLION) 153
TABLE 147 MEXICO: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER,
2017–2024 (USD MILLION) 154
TABLE 148 ROLATAM: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT,
2017–2024 (USD MILLION) 154
TABLE 149 ROLATAM: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION,
2017–2024 (USD MILLION) 155
TABLE 150 ROLATAM: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER,
2017–2024 (USD MILLION) 155
TABLE 151 MEA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT,
2017–2024 (USD MILLION) 158
TABLE 152 MEA: SYNTHESIZED OLIGOS MARKET, BY PRODUCT, 2017–2024 (USD MILLION) 158
TABLE 153 MEA: SYNTHESIZED OLIGOS MARKET, BY TYPE, 2017–2024 (USD MILLION) 159
TABLE 154 MEA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION,
2017–2024 (USD MILLION) 159
TABLE 155 MEA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS,
BY TYPE, 2017–2024 (USD MILLION) 160
TABLE 156 MEA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2017–2024 (USD MILLION) 160
TABLE 157 MEA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER,
2017–2024 (USD MILLION) 161


LIST OF FIGURES

FIGURE 1 RESEARCH DESIGN 24
FIGURE 2 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION,
AND REGION 27
FIGURE 3 DATA TRIANGULATION METHODOLOGY 29
FIGURE 4 SYNTHESIZED OLIGOS DOMINATES THE OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2019—2024 (USD MILLION) 31
FIGURE 5 OLIGONUCLEOTIDE-BASED DRUGS SEGMENT TO RECORD HIGHEST GROWTH, 2019–2024 (USD MILLION) 32
FIGURE 6 PREDESIGNED OLIGOS TO DOMINATE THE OLIGONUCLEOTIDE
SYNTHESIS MARKET 33
FIGURE 7 THERAPEUTIC APPLICATIONS HOLD THE LARGEST MARKET SHARE 33
FIGURE 8 HOSPITALS TO GROW AT THE HIGHEST CAGR IN THE END-USER MARKET 34
FIGURE 9 NORTH AMERICA HELD LARGEST SHARE IN 2018 AND TO RECORD HIGHEST CAGR (2019–2024) 35
FIGURE 10 INCREASING USE OF SYNTHESIZED OLIGOS IN MOLECULAR DIAGNOSTICS AND CLINICAL APPLICATIONS ARE DRIVING MARKET GROWTH 36
FIGURE 11 OLIGONUCLEOTIDE-BASED DRUGS TO DOMINATE THE MARKET,
2019–2024 (USD MILLION) 37
FIGURE 12 PREDESIGNED OLIGOS TO COMMAND THE LARGEST SHARE OF THE OLIGONUCLEOTIDE SYNTHESIS MARKET DURING THE FORECAST PERIOD 37
FIGURE 13 PCR HELD THE LARGEST SHARE OF THE ASIA PACIFIC RESEARCH APPLICATIONS MARKET IN 2019 38
FIGURE 14 DNA & ANTISENSE OLIGOS TO REGISTER THE HIGHEST GROWTH RATE DURING THE FORECAST PERIOD 39
FIGURE 15 HOSPITALS SEGMENT TO WITNESS HIGHEST CAGR, 2019—2024 (USD MILLION) 39
FIGURE 16 THE US TO RECORD THE HIGHEST CAGR DURING THE FORECAST PERIOD 40
FIGURE 17 OLIGONUCLEOTIDE SYNTHESIS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 41
FIGURE 18 SYNTHESIZED OLIGOS TO RECORD HIGHEST CAGR DURING
THE FORECAST PERIOD 49
FIGURE 19 THERAPEUTIC APPLICATIONS TO OFFER LUCRATIVE GROWTH OPPORTUNITIES FOR MARKET PLAYERS DURING 2019—2024 64
FIGURE 20 HOSPITALS TO DOMINATE THE OLIGONUCLEOTIDE SYNTHESIS MARKET DURING THE FORECAST PERIOD 79
FIGURE 21 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET SNAPSHOT 87
FIGURE 22 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET SNAPSHOT 99
FIGURE 23 APAC: OLIGONUCLEOTIDE SYNTHESIS MARKET SNAPSHOT 126
FIGURE 24 LATAM: OLIGONUCLEOTIDE SYNTHESIS MARKET SNAPSHOT 146
FIGURE 25 MEA: OLIGONUCLEOTIDE SYNTHESIS MARKET SNAPSHOT 156
FIGURE 26 KEY DEVELOPMENTS IN THE OLIGONUCLEOTIDE SYNTHESIS MARKET
(JAN 2016-JAN 2019) 162
FIGURE 27 MARKET EVOLUTION FRAMEWORK 163
FIGURE 28 GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SHARE ANALYSIS
(FOR RESEARCH AND DIAGNOSTICS), BY KEY PLAYER, 2017 164
FIGURE 29 MNM DIVE-VENDOR COMPARISON MATRIX: EXOSOMES MARKET 170
FIGURE 30 AGILENT TECHNOLOGIES: COMPANY SNAPSHOT 173
FIGURE 31 EUROFINS SCIENTIFIC GROUP: COMPANY SNAPSHOT 183
FIGURE 32 KANEKA: COMPANY SNAPSHOT 186
FIGURE 33 GENERAL ELECTRIC COMPANY (GE): COMPANY SNAPSHOT 190
FIGURE 34 GENSCRIPT: COMPANY SNAPSHOT 193
FIGURE 35 AJINOMOTO: COMPANY SNAPSHOT 196
FIGURE 36 DANAHER CORPORATION: COMPANY SNAPSHOT 198
FIGURE 37 MERCK KGAA: COMPANY SNAPSHOT 204
FIGURE 38 NITTO DENKO CORPORATION: COMPANY SNAPSHOT 208
FIGURE 39 THERMO FISHER SCIENTIFIC: COMPANY SNAPSHOT 211


★調査レポート[オリゴヌクレオチド合成の世界市場予測(~2024年)] ( Oligonucleotide Synthesis Market by Product (Probe, Linkers, Adaptor, Drugs, Reagent, Equipment), Type (Custom, Pre design), Application (PCR, DNA, RNAi, Research, Therapeutic), End User (Hospital, Pharmaceutical, Biotechnology) - Global Forecast to 2024 / BT-2680) 販売に関する免責事項
[オリゴヌクレオチド合成の世界市場予測(~2024年)] ( Oligonucleotide Synthesis Market by Product (Probe, Linkers, Adaptor, Drugs, Reagent, Equipment), Type (Custom, Pre design), Application (PCR, DNA, RNAi, Research, Therapeutic), End User (Hospital, Pharmaceutical, Biotechnology) - Global Forecast to 2024 / BT-2680) についてEメールでお問い合わせ


◆H&Iグローバルリサーチ株式会社のお客様(例)◆